Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

December 31, 2010

Conditions
Poor Quality Sleep
Interventions
DRUG

Lunesta

"Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4."

All Listed Sponsors
collaborator

Sumitomo Pharma America, Inc.

INDUSTRY

lead

Emory University

OTHER

NCT00460993 - Efficacy & Safety of Eszopiclone (Lunesta) in Nursing Home Patients | Biotech Hunter | Biotech Hunter